2014年人类免疫缺陷病毒1型耐药性突变更新
2014 Update of the drug resistance mutations in HIV-1.
作者信息
Wensing Annemarie M, Calvez Vincent, Günthard Huldrych F, Johnson Victoria A, Paredes Roger, Pillay Deenan, Shafer Robert W, Richman Douglas D
机构信息
University of Medical Center Utrecht, The Netherlands.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
Abstract
This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
摘要
国际艾滋病协会美国分会（IAS-USA）2014年7月版的耐药性突变列表更新了上次于2013年3月发布的数据。以下突变已添加到现有类别或药物中：K65E/N已添加到核苷和核苷酸类似物逆转录酶抑制剂（nRTIs）阿巴卡韦、去羟肌苷、恩曲他滨、拉米夫定、司他夫定和替诺福韦的条目中；L100I已添加到非核苷类似物逆转录酶抑制剂（NNRTI）利匹韦林的条目中；F121Y已添加到整合酶链转移抑制剂（InSTIs）度鲁特韦、埃替格韦和拉替拉韦的条目中。关于蛋白酶抑制剂（PIs），不能排除在蛋白酶编码区域以外可能会选择出耐药性。
相似文献
1
2014 Update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
2
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.
3
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3.
4
5
Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.
Antiviral Res. 2024 Oct;230:105988. doi: 10.1016/j.antiviral.2024.105988. Epub 2024 Aug 16.
6
G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.
J Antimicrob Chemother. 2015 Mar;70(3):739-49. doi: 10.1093/jac/dku474. Epub 2014 Nov 20.
7
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81. doi: 10.1128/AAC.00127-06.
8
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Antivir Ther. 2001;6 Suppl 3:25-44.
9
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.
10
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
引用本文的文献
1
Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina.
Viruses. 2025 May 20;17(5):731. doi: 10.3390/v17050731.
2
Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.
Viruses. 2024 Feb 2;16(2):236. doi: 10.3390/v16020236.
3
The Role of Pharmacogenomics in Opioid Prescribing.
Curr Treat Options Oncol. 2022 Oct;23(10):1353-1369. doi: 10.1007/s11864-022-01010-x. Epub 2022 Aug 24.
4
Consistent Quantification of Complex Dynamics via a Novel Statistical Complexity Measure.
Entropy (Basel). 2022 Apr 4;24(4):505. doi: 10.3390/e24040505.
5
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Sci Rep. 2022 Jan 26;12(1):1374. doi: 10.1038/s41598-022-05375-9.
6
Next generation sequencing based in-house HIV genotyping method: validation report.
AIDS Res Ther. 2021 Oct 2;18(1):64. doi: 10.1186/s12981-021-00390-8.
7
Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia.
Epilepsia. 2020 Dec;61(12):2705-2711. doi: 10.1111/epi.16723. Epub 2020 Oct 21.
8
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275.
9
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21.
10
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564.
本文引用的文献
1
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
JAMA. 2014;312(4):410-25. doi: 10.1001/jama.2014.8722.
2
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
J Antimicrob Chemother. 2014 Aug;69(8):2118-22. doi: 10.1093/jac/dku095. Epub 2014 Apr 7.
3
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Antivir Ther. 2014;19(8):819-23. doi: 10.3851/IMP2771. Epub 2014 Apr 4.
4
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.
J Clin Invest. 2013 Sep;123(9):3848-60. doi: 10.1172/JCI67399. Epub 2013 Aug 27.
5
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
J Antimicrob Chemother. 2013 Oct;68(10):2199-204. doi: 10.1093/jac/dkt200. Epub 2013 Jun 7.
6
Update of the drug resistance mutations in HIV-1: March 2013.
Top Antivir Med. 2013 Feb-Mar;21(1):6-14.
7
Human Immunodeficiency Virus Gag and protease: partners in resistance.
Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63.
8
In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Antiviral Res. 2012 Jul;95(1):9-11. doi: 10.1016/j.antiviral.2012.04.007. Epub 2012 May 4.
9
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.
Zotero 插件